Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
2001 1
2009 3
2010 1
2011 1
2012 1
2013 1
2016 2
2017 4
2018 3
2019 6
2020 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Mixed-chemical exposure and predicted effects potential in wadeable southeastern USA streams.
Bradley PM, Journey CA, Berninger JP, Button DT, Clark JM, Corsi SR, DeCicco LA, Hopkins KG, Huffman BJ, Nakagaki N, Norman JE, Nowell LH, Qi SL, VanMetre PC, Waite IR. Bradley PM, et al. Among authors: nakagaki n. Sci Total Environ. 2019 Mar 10;655:70-83. doi: 10.1016/j.scitotenv.2018.11.186. Epub 2018 Nov 13. Sci Total Environ. 2019. PMID: 30469070 Free article.
Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors.
Iwama E, Sakai K, Hidaka N, Inoue K, Fujii A, Nakagaki N, Ota K, Toyozawa R, Azuma K, Nakatomi K, Harada T, Hisasue J, Sakata S, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I. Iwama E, et al. Among authors: nakagaki n. Cancer. 2020 Jan 1;126(1):219-227. doi: 10.1002/cncr.32481. Epub 2019 Sep 10. Cancer. 2020. PMID: 31503343 Free article.
Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
Otsubo K, Sakai K, Takeshita M, Harada D, Azuma K, Ota K, Akamatsu H, Goto K, Horiike A, Kurata T, Nakagaki N, Nosaki K, Iwama E, Nakanishi Y, Nishio K, Okamoto I. Otsubo K, et al. Among authors: nakagaki n. Oncologist. 2019 Aug;24(8):1022-1026. doi: 10.1634/theoncologist.2019-0101. Epub 2019 Apr 25. Oncologist. 2019. PMID: 31023862 Free PMC article.
Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.
Iwama E, Goto Y, Murakami H, Tsumura S, Sakashita H, Mori Y, Nakagaki N, Fujita Y, Seike M, Bessho A, Ono M, Nishitsuji M, Akamatsu H, Morinaga R, Akagi T, Shimose T, Tokunaga S, Yamamoto N, Nakanishi Y, Sugio K, Okamoto I. Iwama E, et al. Among authors: nakagaki n. Oncologist. 2020 Apr;25(4):306-e618. doi: 10.1634/theoncologist.2019-0728. Epub 2019 Oct 30. Oncologist. 2020. PMID: 32297438 Free PMC article.
Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).
Fukuda M, Kitazaki T, Ogawara D, Ichiki M, Mukae H, Maruyama R, Nakagaki N, Shimada M, Ikeda T, Kishimoto J, Harada T, Seto T, Ebi N, Takayama K, Okamoto I, Ichinose Y, Sugio K. Fukuda M, et al. Among authors: nakagaki n. Lung Cancer. 2019 Jun;132:1-8. doi: 10.1016/j.lungcan.2019.01.008. Epub 2019 Apr 5. Lung Cancer. 2019. PMID: 31097081 Clinical Trial.
20 results